# Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06928389/  
OnCo record `nct06928389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.

## Summary

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06928389 by Akeso, with 536 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05. Interventions recorded: Ivonescimab, docetaxel, Placebo, docetaxel. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06928389
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy
- Sponsor: Akeso
- Enrolled: 536

## Sources

- ClinicalTrials.gov NCT06928389: https://clinicaltrials.gov/study/NCT06928389

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06928389.json